Axsome Therapeutics Stock News

This company has several potential catalysts on the way.

Axsome Therapeutics (NASDAQ:AXSM) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open.Consensus EPS estimate is -$0.96.

Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time

Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:40 PM Eastern Time.

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorder

Axsome Therapeutics said that it was informed by the FDA that it should be able to perform a required inspection of a contract manufacturing facility prior to the PDUFA date in April.

Benzingas weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the duel is between a pair of Black-owned companies in the biopharmaceutical sector : Axsome Therapeutics Inc. (NASDAQ: AXSM ) and Global Blood Therapeutics Inc. (NASDAQ: GBT ). The Case For Axsome Therapeutics: This New York City-based company was founded in 2012 by the Haitian-born Dr. Herriot Tabuteau , who has served as its chairman and CEO since the company began. Tabuteau has a Bachelor of Arts in molecular biology and biochemistry from Wesleyan University and an M.D. from Yale University School of Medicine. He previously worked as an analyst for Goldman Sachs (NYSE: GS ), where he specialized in healthcare analysis, and for HealthCor , a fund focused on healthcare and life sciences. Dr. Herriot Tabuteau Axsome Therapeutics, which has been publicly-traded since 2015, focuses on treating disorders impacting the central nervous system including depression, chronic pain, narcolepsy, fibromyalgia and Alzheimer''s disease.

Benzinga's weekly Stock Wars matches up two leaders in a major industry sector with the goal of determining which company is the better investment. This week, in tribute to Black History Month, the du

The stock receives a positive analyst thumbs-up after it issues a business update.

The stock receives a positive analyst thumbs-up after it issues a business update.

These two biotechs have potential catalysts to look forward to in 2022.

Axsome (AXSM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co

These three stocks are poised for a major breakout in 2022.

Gainers: Marin Software MRIN +43%, QuinStreet (QNST) +5%, Axsome Therapeutics (AXSM) +4%, CarParts.com PRTS +3%, Curis CRIS +3%.Losers: Annexon (ANNX) -5%, Dogness (DOGZ) -4%,